Regulatory T Cells in Neuroimmunological Disease Therapeutics

Dear Colleagues,

Overview:

We invite submissions for a Special Issue focused on the role of regulatory T cells (Tregs) in neuroimmunological disease therapeutics. Neuroimmunological diseases encompass a wide range of conditions where immune dysfunction plays a critical role in neurological pathologies. Understanding the contribution of Tregs and their therapeutic potential is the central theme of this Special Issue.

Topics of Interest:

• Autoimmune Diseases: Explore the involvement of Tregs in autoimmune neuroimmunological diseases such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and Guillain–Barré syndrome. Investigate Treg-based therapies aimed at modulating autoimmunity.
• Immunomodulation: Examine how Tregs can be harnessed to modulate the immune responses contributing to neuroinflammation. Discuss the impact of existing immunomodulatory therapies on Treg function.
• Neuroprotection: Investigate the neuroprotective effects of Tregs in various neuroimmunological diseases. Explore how Tregs can limit immune-mediated neuronal damage, reduce inflammation, and support tissue repair.
• Immune–Brain Crosstalk: Delve into the role of Tregs in influencing the communication between the immune system and the central nervous system (CNS). Explore Treg-based approaches for conditions associated with gut dysbiosis, such as autism spectrum disorders and mood disorders.
• Treg-Based Therapies: Present research on Treg-based therapies tailored to specific neuroimmunological diseases. Discuss strategies for Treg isolation, expansion, and administration, as well as the potential of genetically modified Tregs.

Challenges and Future Directions:

Highlight the challenges in translating Treg research into clinical therapies. Discuss the need for optimizing protocols, ensuring long-term safety, and understanding the effectiveness of Treg-based treatments across diverse patient populations.

We welcome original research articles, reviews, and perspectives that contribute to our understanding of Tregs in neuroimmunological disease therapeutics. Submissions should align with the theme of the Special Issue and adhere to the journal's guidelines.

Contact:

For inquiries and submissions, please contact [email protected]

Join us in exploring the promising role of Tregs in revolutionizing the treatment landscape for neuroimmunological diseases. Share your insights and contribute to advancing our knowledge in this rapidly evolving field.

Dr. Michel Edwar Mickael
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Treg
• multiple sclerosis
• Alzheimer's disease
• Parkinson's disease
• depression
• immune therapy
• immunomodulation